Malave Luis's Form 4 filing
Glucotrack, Inc. (GCTK) · filed Mar 31, 2025
- Accession no.
- 0001474506-25-000071
- Filed
- Mar 31, 2025, 8:17 AM ET
- Trade date
- Sep 30, 2021-Mar 26, 2025
- Filing delay
- 1,278 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 12 non-derivative transactions and 5 derivative transactions. It was filed 1278 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Malave LuisCIK 0001395781 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 30, 2021 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +8 | $0.00 | $0 | 8 | Direct | |
| Dec 31, 2021 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +11 | $0.00 | $0 | 19 | Direct | |
| Mar 31, 2022 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +25 | $0.00 | $0 | 44 | Direct | |
| Jun 30, 2022 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +34 | $0.00 | $0 | 78 | Direct | |
| Oct 4, 2022 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +44 | $0.00 | $0 | 122 | Direct | |
| Jan 9, 2023 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +29 | $0.00 | $0 | 151 | Direct | |
| Apr 20, 2023 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +121 | $0.00 | $0 | 272 | Direct | |
| Dec 31, 2023 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +362 | $0.00 | $0 | 634 | Direct | |
| Apr 8, 2024 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +489 | $0.00 | $0 | 1,123 | Direct | |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | CConversionAcquired | +6,886 | $31.20 | +$214,843.2 | 8,009 | Direct | |
| Mar 12, 2025 | Common Stock, par value $0.001 per share | XIn-the-money exerciseAcquired | +133,532 | $0.00 | $0 | 141,541 | Direct | |
| Mar 26, 2025 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +2,076 | $0.00 | $0 | 143,617 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 18, 2024 | Common Stock, par value $0.001 per share | PPurchaseAcquired | +6,411 | $200,000.00 | – | – | Direct | Price outlier |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | CConversionDisposed | −6,886 | $214,831.00 | – | 0 | Direct | Price outlier |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +6,886 | –F4 | – | 6,886 | Direct | |
| Nov 14, 2024 | Common Stock, par value $0.001 per share | AGrant or awardAcquired | +133,532 | –F4 | – | 6,886 | Direct | |
| Mar 12, 2025 | Common Stock, par value $0.001 per share | XIn-the-money exerciseDisposed | −133,532 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise").
Referenced by the price of 2 transactions in Table II.
Remarks
Note: On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "2025 Reverse Split," and together with the 2024 Reverse Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.